Clinical Trials Browser

Phase 2/3 × spartalizumab × Other solid neoplasm × Clear all

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Phase 2/3 Unknown

Other solid neoplasm

Advanced Solid Tumor